Less than a tenth of individuals eligible to benefit from weight-loss injections like Wegovy can access them, states the WHO as it publishes its first guidance on the therapies.
Considering in excess of 1,000,000,000 people worldwide now living with obesity, it is urging more widespread and fairer availability to GLP-1 medication.
Based on projections, more than two billion will be obese by 2030 without intervention.
"The new guidelines recognises that excess weight is a long-term condition that can be addressed with holistic and ongoing treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are major barriers to widespread access to the jabs that can aid individuals in losing considerable weight, explains the organization.
Skinny Jab Shortage
Despite the present most favorable scenario, the manufacturing of such drugs could only cover around 100 million people – less than 10% of eligible patients, according to the health organization.
The advice urges nations and manufacturers to widen availability, via measures such as patent sharing.
Exclusive production rights on the active ingredient – the main component of the drug Wegovy – is scheduled to end in multiple nations in 2026.
The Way Obesity Jabs Function
GLP-1 drugs mimick a body's own hormone to reduce digestion speed, suppress the appetite and enhance satiety so people consume fewer calories.
Patients commonly see weight reduction after several weeks of beginning the regular doses.
Evidence points to people may put most of the weight back on within a year of stopping the drug, as their typical appetite resume.
To be overweight or obese increases your chance for experiencing diseases, such as type 2 diabetes, heart disease, stroke, and certain malignancies.
Excess weight impacts individuals in all nations and was associated with over three and a half million fatalities worldwide in 2024, per the WHO.
